Browse the evidence

NCL-1 (TRIM2/Brat) mediates lifespan extension in major longevity pathways by limiting nucleolar size and reducing fibrillarin expression.

In C. elegans, the protein NCL-1 is essential for the lifespan benefits of various longevity pathways. It works by reducing the size of the nucleolus and lowering fibrillarin levels. This suggests that regulating nucleolar function is a critical step in extending life in these genetic models.

Reducing brain-specific IGF-1 receptor signaling lowers somatotropic hormone output (GH/IGF-I), which extends mean lifespan and delays mortality in mammals.

This research suggests that lower levels of Growth Hormone and IGF-1 signaling are associated with a longer life in mammals. While this is a genetic study in mice, it challenges the common practice of using GH to combat aging in humans, implying that high levels of these hormones might carry a risk of shortened lifespan.

Perilipin 1 (PLIN1) acts as a gatekeeper for lipid storage by sequestering lipases (ATGL and HSL) from cytosolic lipid droplets in the basal state, thereby suppressing lipolysis until hormonal stimulation triggers phosphorylation and enzyme recruitment.

In fat cells, a protein called PLIN1 acts as a protective coat that keeps fat-burning enzymes away from stored fat when you are at rest or fed. This prevents unnecessary fat loss. Only when your body signals a need for energy (via hormones like adrenaline) does this coat get modified to allow enzymes access. This highlights that fat storage is an active, regulated process, not just passive accumulation.

Mutations in the AMPK gamma-2 subunit (PRKAG2) cause a gain-of-function effect leading to excessive glycogen storage and cardiac hypertrophy.

For individuals with PRKAG2 mutations, excessive AMPK activity leads to dangerous glycogen accumulation in the heart. This highlights the importance of precise regulation of energy-sensing pathways in cardiac tissue.

Leptin signaling in POMC neurons is essential for energy homeostasis, and leptin deficiency causes obesity, which can be corrected by leptin administration.

Leptin is crucial for weight regulation, but it only works as a treatment for those with a specific genetic deficiency. It is not a general weight-loss drug for the majority of people with obesity.

Adipokine-based therapies face major biological roadblocks including lack of efficacy in humans despite rodent success, incomplete understanding of mechanisms, and adverse side effects.

Developing new obesity drugs based on adipokines is difficult because success in mice often fails in humans, mechanisms are often unknown, and side effects are common. This makes the drug development process long, expensive, and prone to failure.

Exogenous leptin therapy is effective in treating obesity and metabolic disorders only in individuals with congenital leptin deficiency or generalized lipodystrophy, but is ineffective for the majority of people with common obesity.

Leptin therapy is not a weight-loss drug for the general public. It is a life-saving treatment for rare genetic conditions where the body produces no leptin. For most people with obesity, adding more leptin does not work because the body has stopped listening to it.

The hyperinsulinemic euglycemic clamp is the gold standard method for quantifying insulin sensitivity in vivo, offering high reproducibility and the ability to distinguish hepatic from peripheral resistance.

The hyperinsulinemic euglycemic clamp is the most accurate way to measure insulin sensitivity and is the research gold standard. However, due to its complexity and cost, it is reserved for research. Clinicians use simpler, less accurate surrogate tests for routine patient care.

Dual-PPARα/γ agonists (glitazars) like muraglitazar, tesaglitazar, and aleglitazar have largely failed in clinical development for type 2 diabetes and cardiovascular disease due to severe safety concerns, including heart failure, renal dysfunction, and increased mortality.

Do not seek out dual-PPAR agonists like muraglitazar or aleglitazar. These drugs were developed for diabetes and heart health but were withdrawn from the market because they caused serious side effects like heart failure and kidney problems. Stick to established treatments with proven safety profiles.

Daily subcutaneous administration of recombinant human leptin normalizes hyperphagia and induces significant weight loss in patients with congenital leptin deficiency.

If you have been diagnosed with congenital leptin deficiency, daily injections of recombinant leptin are the standard of care and can significantly reduce hunger and promote weight loss. This treatment is not effective for typical obesity where leptin levels are already high.

Orexin deficiency causes narcolepsy, characterized by excessive daytime sleepiness, cataplexy, and fragmented sleep-wake cycles, due to the loss of orexin neurons in the hypothalamus.

If you experience excessive daytime sleepiness, cataplexy, or fragmented sleep, consult a specialist. Narcolepsy is a biological condition caused by a lack of orexin, not a lifestyle choice. Diagnosis involves measuring orexin levels in cerebrospinal fluid.

NOS1-expressing glutamatergic neurons in the preoptic area link thermal sensory information to NREM onset and body cooling.

This is a basic science finding explaining how warmth triggers sleep at the neural level. It confirms that sleep initiation is an active process driven by specific brain circuits responding to warmth, rather than a passive state.

Type 2 diabetes is a complex metabolic disorder driven by a strong genetic predisposition involving at least 75 identified common genetic loci, with heritability further modulated by epigenetic mechanisms such as DNA methylation in response to environmental factors.

Your risk for Type 2 Diabetes is significantly influenced by your genetics, with over 75 specific gene variants linked to the disease. However, this risk is not fixed; it interacts with your environment through epigenetic changes (like DNA methylation). This means that while you cannot change your DNA, you can influence how those genes are expressed through lifestyle factors, potentially mitigating genetic risk.

Testosterone administration is absolutely contraindicated in men with clinical (metastatic) prostate cancer because androgen supplementation promotes tumor growth and progression.

If you have been diagnosed with metastatic prostate cancer, you must NOT take testosterone replacement therapy. It will cause your cancer to grow and spread. The standard treatment is to lower testosterone levels (androgen ablation).

Gastrointestinal (GI) surgery is the only current treatment capable of achieving significant, long-term sustainable weight loss, primarily by altering the physiology and circulating levels of appetite-regulating gut hormones.

If you are struggling with obesity and other methods haven't provided lasting results, GI surgery is currently the only treatment proven to offer significant, long-term weight loss. This works by changing your gut hormones (like GLP-1 and PYY) to naturally reduce appetite. While surgery has risks and costs, it serves as the benchmark for what hormonal therapies aim to achieve safely.

Inhibition of IL-11 signaling through genetic deletion or therapeutic antibody administration extends mammalian healthspan and lifespan by mitigating age-associated metabolic decline, frailty, and tissue fibrosis.

This research suggests that targeting the IL-11 pathway could be a viable strategy for extending healthspan and lifespan in humans. While the study was conducted in mice, the findings support the potential of anti-IL-11 therapies, which are already in clinical trials for other conditions, to mitigate age-related decline. For now, this remains a preclinical finding, but it highlights IL-11 as a promising target for future longevity interventions.

LEAP2 acts as a GHSR antagonist that hyperpolarizes arcuate NPY neurons and prevents acyl-ghrelin from activating them, thereby blunting ghrelin's orexigenic effects.

This is a deep biological mechanism showing how your brain processes hunger signals. LEAP2 physically blocks the hunger signal at the neuronal level. This explains why high levels of LEAP2 in obesity might contribute to 'ghrelin resistance,' where the hunger signal is less effective.

Gestational diabetes is associated with increased risks of perinatal complications including hypertensive disorders, preterm delivery, shoulder dystocia, stillbirth, neonatal hypoglycemia, and cesarean delivery.

GDM increases the risk of several serious complications for both mother and baby, including high blood pressure, early delivery, difficult birth, and low blood sugar in the newborn. Proper management is crucial to mitigate these risks.

Skeletal muscle cells secrete 52 novel myokines and 48 additional contraction-regulated myokines, expanding the known human skeletal muscle secretome beyond previously identified proteins like IL-6 and irisin.

Exercise triggers the release of many more signaling proteins than previously known. While we focus on well-known ones like IL-6, this research confirms that muscle contraction triggers a complex, largely uncharted hormonal response that contributes to health benefits.

Lithium extends lifespan and stress resistance by inhibiting GSK-3 (Shaggy in flies), which subsequently activates the transcription factor NRF-2 (CncC), leading to hormetic stress resistance.

The longevity benefits of lithium are mechanistically linked to the inhibition of GSK-3 and the subsequent activation of NRF-2. This pathway enhances cellular stress resistance (hormesis) without requiring autophagy. This suggests that GSK-3 inhibitors or NRF-2 activators could be viable anti-aging strategies, provided they are dosed to avoid over-activation of NRF-2, which can be detrimental to lifespan.

In rodents, resistin administration impairs glucose tolerance and insulin action, while resistin deletion improves insulin sensitivity and glucose homeostasis.

This finding is specific to rodents and does not directly translate to human treatment. Human resistin biology is different, and targeting resistin in humans has not yielded the same clear benefits as in mice.

MC4R mutations are the most common cause of monogenic obesity, found in 5-6% of severe early-onset obesity cases, and lead to hyperphagia, increased lean mass, and accelerated linear growth.

If you have severe early-onset obesity, ask about MC4R testing. It is the most common genetic cause, and identifying it opens the door to specific treatments.

MuRF1 and MuRF2 function cooperatively to downregulate anabolic stretch signals (ANP, MLP) and translational machinery (mTOR pathway) in muscle tissue.

This paper identifies the specific molecular pathway (MuRF1/2 -> mTOR/Stretch signals) that controls muscle growth. Understanding this pathway is crucial for developing future drugs to treat muscle wasting diseases, but no such drugs are currently available for human use.

Sibutramine and Rimonabant, previously approved anti-obesity drugs, were withdrawn from the market due to serious adverse effects, specifically increased cardiovascular risk and psychiatric disorders, respectively.

Do not use Sibutramine or Rimonabant. They have been withdrawn from major markets (EU, USA, Canada) due to serious cardiovascular and psychiatric risks. Orlistat is the primary long-term pharmacological option available.